{"id":"https://openalex.org/W4281610097","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.e16031","title":"Effect of hepatic impairment on the pharmacokinetics of ripretinib.","display_name":"Effect of hepatic impairment on the pharmacokinetics of ripretinib.","publication_year":2022,"publication_date":"2022-06-01","ids":{"openalex":"https://openalex.org/W4281610097","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.e16031"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2022.40.16_suppl.e16031","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.e16031","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2022.40.16_suppl.e16031","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5100459422","display_name":"Xiaoyan Li","orcid":"https://orcid.org/0000-0002-9968-7118","observed_orcids":["https://orcid.org/0000-0002-9968-7118"]},"institutions":[{"id":"https://openalex.org/I4210127537","display_name":"Deciphera Pharmaceuticals (United States)","ror":"https://ror.org/038hbfs18","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127537"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xiaoyan Li","raw_affiliation_strings":["Deciphera Pharmaceuticals, LLC, Waltham, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Deciphera Pharmaceuticals, LLC, Waltham, MA;","institution_ids":["https://openalex.org/I4210127537"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082933172","display_name":"Charles M. Psoinos","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127537","display_name":"Deciphera Pharmaceuticals (United States)","ror":"https://ror.org/038hbfs18","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127537"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Charles M Psoinos","raw_affiliation_strings":["Deciphera Pharmaceuticals, Waltham, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Deciphera Pharmaceuticals, Waltham, MA;","institution_ids":["https://openalex.org/I4210127537"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111905871","display_name":"Mark Joel Shelton","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark Joel Shelton","raw_affiliation_strings":["Certara, Raleigh, NC;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Certara, Raleigh, NC;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039648531","display_name":"Farida Abane","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127537","display_name":"Deciphera Pharmaceuticals (United States)","ror":"https://ror.org/038hbfs18","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127537"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Farida Abane","raw_affiliation_strings":["Deciphera, Waltham, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Deciphera, Waltham, MA;","institution_ids":["https://openalex.org/I4210127537"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021367289","display_name":"Mark Matson","orcid":"https://orcid.org/0009-0000-4058-7211","observed_orcids":["https://orcid.org/0009-0000-4058-7211"]},"institutions":[{"id":"https://openalex.org/I4210108021","display_name":"Prism Clinical Research","ror":"https://ror.org/011bmz187","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210108021"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark A. Matson","raw_affiliation_strings":["Prism Research, St. Paul, MN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Prism Research, St. Paul, MN;","institution_ids":["https://openalex.org/I4210108021"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067531794","display_name":"Samuel Oberstein","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127537","display_name":"Deciphera Pharmaceuticals (United States)","ror":"https://ror.org/038hbfs18","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127537"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Samuel Oberstein","raw_affiliation_strings":["Deciphera Pharmaceuticals, Inc., Waltham, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Deciphera Pharmaceuticals, Inc., Waltham, MA;","institution_ids":["https://openalex.org/I4210127537"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5029244284","display_name":"Rodrigo Ruiz\u2010Soto","orcid":"https://orcid.org/0000-0003-3057-7735","observed_orcids":["https://orcid.org/0000-0003-3057-7735"]},"institutions":[{"id":"https://openalex.org/I4210127537","display_name":"Deciphera Pharmaceuticals (United States)","ror":"https://ror.org/038hbfs18","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127537"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rodrigo Ruiz-Soto","raw_affiliation_strings":["Deciphera Pharmaceuticals, Waltham, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Deciphera Pharmaceuticals, Waltham, MA;","institution_ids":["https://openalex.org/I4210127537"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"40","issue":"16_suppl","first_page":"e16031","last_page":"e16031"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.7900000214576721,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.7900000214576721,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11485","display_name":"Gastrointestinal Tumor Research and Treatment","score":0.11259999871253967,"subfield":{"id":"https://openalex.org/subfields/2715","display_name":"Gastroenterology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.03999999910593033,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/liver-dysfunction","display_name":"liver dysfunction","score":0.9179999828338623},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9300000071525574},{"id":"https://openalex.org/keywords/cyp3a-substrates","display_name":"CYP3A substrates","score":0.6769999861717224},{"id":"https://openalex.org/keywords/gastrointestinal-stromal-tumor","display_name":"gastrointestinal stromal tumor","score":0.9079999923706055},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.9200000166893005},{"id":"https://openalex.org/keywords/unbound-fraction","display_name":"unbound fraction","score":0.6639999747276306},{"id":"https://openalex.org/keywords/child-pugh-score","display_name":"Child-Pugh score","score":0.6579999923706055},{"id":"https://openalex.org/keywords/drug-safety-in-liver-disease","display_name":"drug safety in liver disease","score":0.6819999814033508},{"id":"https://openalex.org/keywords/dose-adjustment","display_name":"dose adjustment","score":0.33899998664855957},{"id":"https://openalex.org/keywords/safety-pharmacology","display_name":"safety pharmacology","score":0.38199999928474426}],"concepts":[{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.8033528327941895},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.566705048084259},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5232499837875366},{"id":"https://openalex.org/C2777477808","wikidata":"https://www.wikidata.org/wiki/Q407595","display_name":"Metabolite","level":2,"score":0.5021078586578369},{"id":"https://openalex.org/C11824378","wikidata":"https://www.wikidata.org/wiki/Q5014970","display_name":"CYP3A","level":4,"score":0.45485639572143555},{"id":"https://openalex.org/C76318530","wikidata":"https://www.wikidata.org/wiki/Q16833590","display_name":"Area under the curve","level":2,"score":0.433228462934494},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.4261191487312317},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.4153735339641571},{"id":"https://openalex.org/C43617362","wikidata":"https://www.wikidata.org/wiki/Q170050","display_name":"Chromatography","level":1,"score":0.40405017137527466},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.38389232754707336},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3405779302120209},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3265010118484497},{"id":"https://openalex.org/C62231903","wikidata":"https://www.wikidata.org/wiki/Q1057","display_name":"Metabolism","level":2,"score":0.15112614631652832},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.14384108781814575},{"id":"https://openalex.org/C526171541","wikidata":"https://www.wikidata.org/wiki/Q407693","display_name":"Cytochrome P450","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2022.40.16_suppl.e16031","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.e16031","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2022.40.16_suppl.e16031","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4412500582","https://openalex.org/W4319758630","https://openalex.org/W3180996181","https://openalex.org/W4280510692","https://openalex.org/W7162649275","https://openalex.org/W2512069451","https://openalex.org/W3182234451","https://openalex.org/W4387600231","https://openalex.org/W4395011252","https://openalex.org/W3163990818"],"abstract_inverted_index":{"e16031":[0],"Background:":[1],"Ripretinib":[2,30],"is":[3],"a":[4,81,106,319],"tyrosine":[5],"kinase":[6,26],"inhibitor":[7],"indicated":[8],"for":[9,184,242,246],"the":[10,121,175],"treatment":[11,23],"of":[12,61,85,93,97,132],"patients":[13],"with":[14,24,41,58,67,90,155,159,163,248,252,282],"advanced":[15],"gastrointestinal":[16],"stromal":[17],"tumor":[18],"who":[19],"have":[20],"received":[21,80],"prior":[22],"\u22653":[25],"inhibitors,":[27],"including":[28],"imatinib.":[29],"and":[31,39,70,76,99,120,127,135,138,148,166,179,221,232,244,278,297,304,311,326],"its":[32],"active":[33],"metabolite":[34],"(DP-5439)":[35],"are":[36,329],"CYP3A":[37],"substrates":[38],"coadministration":[40],"itraconazole":[42],"(CYP3A":[43],"inhibitor)":[44],"increased":[45,273,300],"exposure":[46,308],"to":[47,263,309,318],"each":[48],"analyte":[49],"by":[50,105],"\u0303100%.":[51],"Therefore,":[52],"we":[53],"studied":[54],"ripretinib":[55,86,98,178,194,216,243,301,313],"in":[56,101,174,258,324],"subjects":[57,79,154,260],"varying":[59],"degrees":[60],"hepatic":[62],"impairment":[63],"(HI).":[64],"Methods:":[65],"Subjects":[66],"mild,":[68],"moderate,":[69],"severe":[71,164,213,298,327],"HI":[72,186,253,259,286,299,328],"based":[73],"on":[74,290],"Child-Pugh,":[75],"matched":[77],"healthy":[78,168,188,264],"single":[82],"oral":[83],"dose":[84],"(50":[87],"mg,":[88],"fasting)":[89],"8":[91,158],"days":[92],"PK":[94,113,181,307],"sampling.":[95],"Concentrations":[96],"DP-5439":[100,180,203,227,310,315],"plasma":[102],"were":[103,115,140,144,170,229],"measured":[104],"liquid":[107],"chromatography\u2013tandem":[108],"mass":[109],"spectrometry":[110],"(LC-MS/MS)":[111],"assay.":[112],"parameters":[114],"calculated":[116],"using":[117],"Phoenix":[118],"WinNonlin,":[119],"geometric":[122],"least":[123],"squares":[124],"mean":[125],"ratios":[126],"corresponding":[128],"90%":[129],"confidence":[130],"intervals":[131],"Cmax,":[133],"AUC0-t,":[134],"AUC0-\u221e":[136],"(total":[137],"unbound)":[139],"calculated.":[141],"Unbound":[142,237],"concentrations":[143],"assessed":[145],"at":[146],"Tmax":[147],"24":[149],"hours":[150],"postdose.":[151],"Results:":[152],"Eight":[153],"mild":[156,185,285],"HI,":[157,161,165,192,214],"moderate":[160,191,296,325],"4":[162],"13":[167],"matches":[169],"enrolled.":[171],"As":[172],"shown":[173],"table,":[176],"total":[177,193,215,291],"was":[182,196,200,205,209,218,223,234,239,261,316],"comparable":[183],"vs.":[187],"matches.":[189],"For":[190,212],"AUC":[195,204,302],"\u0303100%":[197,303],"higher":[198,207,220],"(Cmax":[199,208],"comparable),":[201],"whereas":[202,226],"marginally":[206],"32%":[210],"lower).":[211],"AUC0-t":[217],"\u0303160%":[219],"Cmax":[222,233],"\u030324%":[224],"lower,":[225],"AUCs":[228],"\u030350%":[230],"lower":[231],"78%":[235],"lower.":[236],"fraction":[238],"<":[240],"0.6%":[241],"0.2-1.4%":[245],"DP-5439,":[247],"no":[249,288],"clear":[250],"trend":[251],"severity.":[254],"The":[255],"safety":[256],"profile":[257],"similar":[262],"matches;":[265],"common":[266],"adverse":[267],"events":[268],"(in":[269],"\u22652":[270],"subjects)":[271],"included":[272],"lipase":[274],"or":[275],"amylase,":[276],"diarrhea,":[277],"headache.":[279],"Conclusions:":[280],"Consistent":[281],"current":[283],"labeling,":[284],"had":[287],"impact":[289],"PK.":[292],"In":[293],"this":[294],"study,":[295],"163%,":[305],"respectively.":[306],"combined":[312],"+":[314],"impacted":[317],"lesser":[320],"extent.":[321],"Dose":[322],"recommendations":[323],"currently":[330],"under":[331],"development.[Table:":[332],"see":[333],"text]":[334]},"counts_by_year":[{"year":2022,"cited_by_count":1}],"updated_date":"2026-10-12T09:40:04.860316","created_date":"2022-06-12T00:00:00"}